drugset
Drugs / DUK-CPG-001
last change Jan 2025 re-read 3 minutes ago

DUK-CPG-001

targets TLR9 via activation

Developed for
Hodgkins lymphoma · lymphoid neoplasm · myeloid neoplasm · non-Hodgkin lymphoma
Investigated by
Agilent Technologies, Inc. · Cristina Gasparetto · David Rizzieri, MD

Trials 2

today NCT02115126 · Ph 2 NCT02452697 · Ph 2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02115126 Dec 2016 → Jan 2020 Hodgkins lymphoma, non-Hodgkin lymphoma David Rizzieri, MD Withdrawn No outcome recorded
Phase 2 NCT02452697 Jun 2016 → Jul 2022 lymphoid neoplasm, myeloid neoplasm Cristina Gasparetto Unknown Missed primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as DUK-CPG-001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452697 ↗
1

NCT02115126 ↗
Action Activate “TLR9 Agonist, DUK-CPG-001” NCT02115126 ↗
Route Subcutaneous “5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination.” NCT02115126 ↗
Target TLR9 “TLR9 ligand, DUK-CPG-001” NCT02115126 ↗